He Rui, Yuan Xing, Chen Zeran, Zheng Yongfeng
Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan, China.
Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan, China.
Int Immunopharmacol. 2022 Dec;113(Pt B):109444. doi: 10.1016/j.intimp.2022.109444. Epub 2022 Nov 16.
Metastatic triple negative breast cancer is not only the worst prognosis and the strongest invasive subtype of breast cancer, but also the most immunogenic subtype, so it can be reasonably predicted that immunotherapy can play a positive role in the treatment of metastatic triple negative breast cancer. However, the effect of using PD-1/PD-L1 immune checkpoint inhibitors alone is not very ideal. In recent years, the regimen of combined therapy has been emerging. This article reviews the application of combined immunotherapy based on PD-1/PD-L1 inhibitors in metastatic triple negative breast cancer, including chemotherapy, targeted therapy, radiotherapy and oncolytic virus therapy. The problems existing in combined therapy and the possibility of future research are discussed, which can provide a reference for the selection of treatment options for patients with metastatic triple negative breast cancer in different situations.
转移性三阴性乳腺癌不仅是乳腺癌中预后最差、侵袭性最强的亚型，也是免疫原性最强的亚型，因此可以合理预测免疫疗法在转移性三阴性乳腺癌的治疗中能发挥积极作用。然而，单独使用PD-1/PD-L1免疫检查点抑制剂的效果并不十分理想。近年来，联合治疗方案不断涌现。本文综述了基于PD-1/PD-L1抑制剂的联合免疫疗法在转移性三阴性乳腺癌中的应用，包括化疗、靶向治疗、放疗和溶瘤病毒治疗。讨论了联合治疗中存在的问题以及未来研究的可能性，可为不同情况下转移性三阴性乳腺癌患者治疗方案的选择提供参考。
